Suppr超能文献

结节性甲状腺疾病患者的甲状腺素抑制治疗

Thyroxine suppressive therapy in patients with nodular thyroid disease.

作者信息

Gharib H, Mazzaferri E L

机构信息

Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA.

出版信息

Ann Intern Med. 1998 Mar 1;128(5):386-94. doi: 10.7326/0003-4819-128-5-199803010-00008.

Abstract

PURPOSE

To review evidence about thyroxine suppressive therapy in patients with thyroid nodules, including the clinical importance and natural history of nodules and the effects and potential side effects of thyroxine therapy.

DATA SOURCES

English-language articles published from 1986 to December 1996 were identified through searches of the MEDLINE database, selected bibliographies, and personal files.

DATA EXTRACTION

Randomized, controlled trials and nonrandomized trials of thyroxine suppressive therapy for solitary and predominantly solid thyroid nodules were reviewed. In most studies, nodule cytology was evaluated by fine-needle aspiration biopsy. Therapy was considered suppressive if suppression was documented by thyroid-stimulating hormone-releasing hormone tests or sensitive thyroid-stimulating hormone assays. Response was defined as a decrease of 50% or more in nodule size or volume; most recent studies measured nodule size by ultrasonography.

DATA SYNTHESIS

The evidence suggests that thyroxine suppressive therapy fails to shrink most nodules: Only 10% to 20% of nodules responded to this treatment. Fine-needle aspiration biopsy is more reliable in distinguishing benign from malignant nodules. Recent studies suggest that spontaneous decrease in size with complete disappearance of thyroid nodules is not uncommon. No data show that thyroxine therapy arrests further growth in most existing nodules or prevents the emergence of new nodules. Postoperative thyroxine therapy does not seem to prevent recurrence of thyroid nodules except in patients with a history of radiation therapy. Potential adverse effects of long-term suppressive therapy include osteoporosis and heart disease.

CONCLUSIONS

Patients with cytologically benign nodules are best followed without thyroxine treatment. Most benign nodules remain stable in size and remain benign when monitored for a long time. For nodules that increase in size, biopsy should be done again or surgery should be performed.

摘要

目的

回顾关于甲状腺结节患者甲状腺素抑制治疗的证据,包括结节的临床重要性和自然史以及甲状腺素治疗的效果和潜在副作用。

资料来源

通过检索MEDLINE数据库、选定的参考文献和个人档案,确定了1986年至1996年12月发表的英文文章。

资料提取

回顾了针对孤立性及以实性为主的甲状腺结节进行甲状腺素抑制治疗的随机对照试验和非随机试验。在大多数研究中,通过细针穿刺活检评估结节细胞学。如果通过促甲状腺激素释放激素试验或敏感促甲状腺激素测定证明有抑制作用,则认为治疗具有抑制性。反应定义为结节大小或体积减少50%或更多;最近的研究通过超声检查测量结节大小。

资料综合

证据表明,甲状腺素抑制治疗无法使大多数结节缩小:只有10%至20%的结节对这种治疗有反应。细针穿刺活检在区分良性与恶性结节方面更可靠。最近的研究表明,甲状腺结节大小自发减小并完全消失并不罕见。没有数据表明甲状腺素治疗能阻止大多数现有结节的进一步生长或预防新结节的出现。除有放射治疗史的患者外,术后甲状腺素治疗似乎不能预防甲状腺结节复发。长期抑制治疗的潜在不良反应包括骨质疏松和心脏病。

结论

细胞学检查为良性结节的患者最好不进行甲状腺素治疗而进行随访。大多数良性结节大小保持稳定,长期监测时仍为良性。对于大小增加的结节,应再次进行活检或进行手术。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验